Aflibercept versus ranibizumab for treating persistent diabetic macular oedema (Q41511029)

1 October 2017

0 references

Aflibercept versus ranibizumab for treating persistent diabetic macular oedema (English)

1 reference

1 October 2017

1 reference

Kristof R O A Vandekerckhove

series ordinal

1

1 reference

1 October 2017

20 May 2015

1 reference

International Ophthalmology

1 October 2017

1 reference

1 October 2017

35

1 reference

1 October 2017

603-609

1 reference

1 October 2017

4

1 reference

Creative Commons Attribution 4.0 International

1 October 2017

start time

20 May 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s10792-015-0081-7

0 references

cites work

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488481

Intravitreal aflibercept for diabetic macular edema

10 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488481

Vascular endothelial growth factor a in intraocular vascular disease

10 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488481

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

10 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488481

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

10 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488481

The discovery of placenta growth factor and its biological activity.

10 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488481

Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab

10 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488481

Placental growth factor contributes to micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic retinopathy

10 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488481

Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy

10 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488481

Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema

10 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488481

Increased expression of placenta growth factor in proliferative diabetic retinopathy.

10 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488481

Vascular endothelial growth factor suppression times in patients with diabetic macular oedema treated with ranibizumab

10 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488481

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488481

Novel method for analyzing snellen visual acuity measurements

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488481

PlGF-1 and VEGFR-1 pathway regulation of the external epithelial hemato-ocular barrier. A model for retinal edema

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488481

Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488481

Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy

19 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25989873

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25989873

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10792-015-0081-7

1 reference

PMCID

4488481

Dimensions Publication ID

1 October 2017

0 references

1 reference

1 October 2017

1 reference

PMCID

4488481